Compare CLMB & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLMB | EDIT |
|---|---|---|
| Founded | 1982 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 387.6M | 432.8M |
| IPO Year | 1996 | 2016 |
| Metric | CLMB | EDIT |
|---|---|---|
| Price | $26.72 | $2.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $80.00 | $5.30 |
| AVG Volume (30 Days) | 137.7K | ★ 2.0M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | 14.29 | ★ 37.50 |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $652,517,000.00 | $31,937,000.00 |
| Revenue This Year | $7.82 | N/A |
| Revenue Next Year | $5.83 | N/A |
| P/E Ratio | $157.83 | ★ N/A |
| Revenue Growth | 40.14 | ★ 132.64 |
| 52 Week Low | $15.25 | $1.66 |
| 52 Week High | $145.00 | $4.54 |
| Indicator | CLMB | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 71.09 | 37.75 |
| Support Level | $24.09 | $2.36 |
| Resistance Level | $112.00 | $2.73 |
| Average True Range (ATR) | 1.18 | 0.17 |
| MACD | 0.24 | -0.07 |
| Stochastic Oscillator | 91.53 | 10.53 |
Climb Global Solutions Inc is a cloud-based, value-added IT distribution and solutions company specializing in emerging technologies. It operates across the USA, Canada, United Kingdom, and Europe through multiple business units, including Climb Channel Solutions, Sigma, Grey Matter, Interwork, and TechXtend. The company is organized into two reportable operating segments. The Distribution segment distributes technical software to corporate resellers, value-added resellers (VARs), consultants, and systems integrators under the name Climb Channel Solutions. The Solutions segment is a cloud solutions provider and value-added reseller of software, hardware, and services to customers under the name Grey Matter.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.